Topiramate (Topamax) and eating disorders

Topiramate, sold as Topamax, is different from the GLP-1 weight-loss drugs that are most discussed. It is an anticonvulsant, also approved to prevent migraines, and it occupies an unusual position in eating disorders: it has a genuine, if off-label, role in reducing binge and purge behaviors for some people, while at the same time suppressing appetite and causing weight loss. That dual nature, a potential treatment tool that is also a weight-loss agent, is what makes it worth understanding carefully. This page covers both sides.

The therapeutic side

In eating disorder care, topiramate is sometimes prescribed off-label to help reduce the frequency of binge eating and purging, with the strongest interest in binge eating disorder and bulimia.¹²³ "Off-label" means a clinician is prescribing it for a use the FDA has not specifically approved, which is legal and common in medicine when the evidence and clinical judgment support it. When used this way, topiramate is part of a broader treatment plan, alongside therapy and nutritional support, and it is prescribed by a clinician who is targeting the binge-purge behaviors rather than the person's weight. Used appropriately, for the right person, it can be a useful tool in that narrow role.

This use is also genuinely controversial. Topiramate's own labeling lists anorexia, the medical term for loss of appetite, among its side effects,⁴ and to many clinicians, giving an appetite-suppressing drug to people with eating disorders is the wrong tool for this population even where it reduces bingeing. The evidence supports it for reducing binge and purge episodes, not for weight loss, and that line is easy to blur.

The risk side

The same drug suppresses appetite and causes weight loss. In fact, topiramate is one of the two active ingredients in an FDA-approved weight-loss combination medication, which underlines how real its weight effect is.⁵ That creates two distinct risks in the eating disorder population.

This is why the prescriber's judgment matters more than the drug itself. A clinician experienced in eating disorders weighs the potential to reduce bingeing against the weight-loss effect and against the person's specific presentation and history, and would generally avoid topiramate in restrictive illness.

Using it safely

If topiramate is being considered, it should be prescribed and monitored by a clinician who knows the full eating disorder picture, with a clear therapeutic target, a plan for side effects, and honesty about why it is being used. It is not a weight-loss product to reach for, and it is not a standalone fix. If you are already taking it and notice the weight effect pulling you toward restriction or a focus on the scale, that is worth raising with your treatment team rather than managing alone. Our guide on the signs that weight-loss medication use has become disordered may help you name what you are noticing. Do not stop a prescribed medication abruptly without medical advice, since topiramate in particular is usually adjusted gradually.

How topiramate differs from the GLP-1 drugs

It is worth being clear that topiramate is a different kind of drug from semaglutide or tirzepatide. The GLP-1 medications are appetite-suppressing weight and diabetes drugs with no established eating disorder treatment role, covered across our GLP-1 articles. Topiramate is an anticonvulsant with an off-label behavioral target (reducing binges and purges) that happens to also suppress appetite. The shared thread is the weight-loss effect and the misuse risk that comes with it, which is why it belongs in this collection at all.

Next steps

Read about binge eating disorder and bulimia, the conditions where topiramate is most discussed, or search for licensed programs for an assessment with a clinician who can weigh medication options properly.